Antitumor effects of the vitamin D analogues UVB1 and EM1 on Breast Cancer Patient Derived Xenografts

FERRONATO MJ; NADAL SERRANO M; ARRIBAS J ; BERNADÓ C ; ARENAS LA HUERTA E; FALL Y; MASCARÓ E; VITALE C ; GUEVARA JA ; IBARRA A; CURINO AC; FACCHINETTI MM

Mar del Plata

Congreso; LXIII congreso anual de la Sociedad Argentina de Investigación Clinica; 2018

Sociedad Argentina de Investigacion Clinica

Despite advances in the treatment of HER2 positive and Triple Negative (TN) Breast Cancer (BC), mortality remains high due to intrinsic or acquired resistance to therapy. Therefore, new candidates to treat these subtypes of tumors are needed. Patient-Derived Xenografts (PDX) generated from recent tumor samples recapitulate the diversity of breast cancer being a powerful preclinical tool for testing new drugs. Previously, the Vitamin D analogues UVB1 and EM1 have demonstrated antitumoral effects in preclinical studies employing cell lines and animal models. Hence, the aim of the present study was to evaluate the antineoplastic effects of UVB1 and EM1 on cells derived from HER2-positive and TNBC- PDXs. The results showed that the analogue UVB1 reduced cell viability of the skin metastatic HER2-positive BC PDX118 and its Trastuzumab-emtansine PDX118 resistant cells (crystal violet assays, p